Biocon Ltd.

NSE: BIOCON | BSE: 532523 | ISIN: INE376G01013 | Industry: Biotechnology
| Mid-range Performer
358.9500 -0.55 (-0.15%)
NSE Sep 24, 2025 15:53 PM

logo
Biocon Ltd.
12 Feb 2024
358.95
-0.15%
Axis Direct
The company's capital allocation is on two fronts - R&D and the acquisition of Viatris.This has resulted in returns ratios falling below ~10% despite growth in the business. A huge looming net debt of $1.2 Bn could lead to further stake dilution in Biocon biologics. Recommendation: HOLD
Institutional Investors have increased holdings from 21.40% to 28.87% in Jun 2025 qtr.
More from Biocon Ltd.
Recommended